Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance
Guidance tracker
What ALKEM guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 20 Aug 2026 | Alkem Laboratories filed the transcript of its Q1 FY2027 earnings conference call, held on 14 August 2026. Management said revenue from operations was INR3,740 crores, up close to 11% year-on-year; India sales were INR2,497 crores (up 10.3%) and international sales were INR1,222 crores (up 16%). Management said... NSE copy | -11.7 % | +13.8 % | -3.5 % |
| 01 Jun 2026 | Alkem Laboratories filed the transcript of its Q4 FY2026 earnings conference call held on 28 May 2026. Management said FY26 EBITDA crossed INR3,000 crores; Q4 total revenue from operations was INR36,033 million (up 14.6% Y-o-Y) and FY26 revenue was INR1,47,123 million (up 13.5%). Management guided that the tax rate... NSE copy | -21.7 % | +10.9 % | +0.1 % |
| 28 May 2026 | Alkem Laboratories filed its press release and analyst presentation on Q4FY26 and FY26 results, dated May 28, 2026. Q4FY26 total revenue from operations was ₹36,033 million, up 14.6% YoY; EBITDA was ₹5,174 million (14.4% margin vs 12.4% in Q4FY25); net profit after non-controlling interest was ₹2,365 million, down... NSE copy | -21.7 % | +10.9 % | +0.1 % |
| 18 Feb 2026 | Alkem Laboratories filed an updated investor meet presentation on Alkem MedTech's strategic way forward, for a meet held on 18 February 2026 at 4:30 p.m. The presentation cites a global MedTech market of $680 billion, projected to reach $870 billion by 2030, and an Indian MedTech market of $16 billion in 2025,... NSE copy | -22.7 % | +14.6 % | +0.9 % |
| 16 Feb 2026 | Alkem Laboratories filed an investor meet presentation on Alkem MedTech's strategic way forward, to be held on February 18, 2026 at 4:30 p.m. The presentation covers a global MedTech market of $680Bn (2025), projected to reach $870Bn by 2030, and an India market of $16Bn (2025) projected to reach $30Bn by 2030... NSE copy | -22.7 % | +14.6 % | +0.9 % |
| 16 Feb 2026 | Alkem Laboratories filed the transcript of its Q3 FY26 earnings conference call, held on 13 February 2026. Management reported Q3 FY26 total revenue of INR37,368 million (up 10.7% YoY), international sales of INR12,157 million (up 26.6%), India sales of INR24,959 million (up 5.5%), EBITDA of INR8,280 million (9%... NSE copy | -22.7 % | +14.6 % | +0.9 % |
| 13 Feb 2026 | Alkem Laboratories filed its press release and analyst presentation on Q3 and 9MFY26 results, dated 13 February 2026. Q3 FY26 total revenue from operations was ₹37,368 million, up 10.7% YoY; India sales were ₹24,959 million (up 5.5%) and international sales were ₹12,157 million (up 26.6%). EBITDA was ₹8,280... NSE copy | -22.7 % | +14.6 % | +0.9 % |
| 19 Nov 2025 | Alkem Laboratories filed the transcript of its Q2 & H1 FY26 earnings conference call, held on 13 November 2025. Management said Q2 FY26 revenue from operations was a record INR40,010 million, up 17.2% Y-o-Y; India sales INR27,660 million (up 12.4%); U.S. sales INR7,649 million (up 28%); non-U.S. sales INR4,241... NSE copy | +1.6 % | +10.7 % | +1.4 % |
| 19 Aug 2025 | Alkem Laboratories filed the transcript of its Q1 FY2026 earnings conference call, held on 12 August 2025. Management reported Q1 FY26 total revenue from operations of INR33,711 million, up 11.2% Y-o-Y, and EBITDA of INR7,391 million, up 21.4%, at a margin of 21.9%. Net profit after minority interest was INR6,643... NSE copy | +11.1 % | +17.2 % | -0.1 % |
| 02 Jun 2025 | Alkem Laboratories filed the transcript of its Q4 FY2025 earnings conference call held on 29 May 2025. Management reported Q4 FY25 revenue from operations of Rs 31,438 million (up 7.1% YoY), India sales of Rs 21,355 million (up 8.1%), international sales of Rs 9,747 million (up 7.2%) and net profit of Rs 3,059... NSE copy | +4.2 % | +7.1 % | +1.4 % |
| 19 Mar 2025 | Alkem Laboratories filed an investor presentation for its analyst/institutional investor meetings at the HSBC Global Investment Summit 2025 in Hong Kong on 24 and 25 March 2025. The presentation states revenue from global operations of INR 125+ Bn in FY24, with about 70% of revenue from India, and market... NSE copy | +4.2 % | +7.1 % | +1.4 % |
| 11 Feb 2025 | Alkem Laboratories filed the transcript of its Q3 FY2025 earnings conference call, held on 7 February 2025. Management reported Q3 revenue from operations of INR 33,743 million (up 1.5% Y-o-Y) and 9M revenue of INR 98,208 million (up 0.9%); Q3 EBITDA of INR 7,594 million at a 22.5% margin; Q3 net profit of INR... NSE copy | +4.2 % | +7.1 % | +1.4 % |
| 18 Nov 2024 | Alkem Laboratories filed the transcript of its Q2 FY2025 earnings conference call held on 13 November 2024. Management (CEO Dr. Vikas Gupta) said H1 FY25 EBITDA was INR 13,615 million at a 21.1% margin versus 17.7% in H1 FY24, with H1 net profit of INR 12,338 million (up 36% Y-o-Y); Q2 net profit was INR 6,886... NSE copy | +5.2 % | +1.5 % | -6.8 % |
Filings tagged as guidance, newest first (13 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 12 Nov 2026 | Management change | Alkem Laboratories filed its press release and analyst presentation on Q2 and H1 FY27 results (quarter ended September 30, 2026), dated November 12, 2026. Total revenue from operations was ₹45,520 million, up 13.8% YoY; India sales were ₹30,275 million (up 9.5% YoY) and International sales were ₹14,540 million (up... NSE copy |
| 20 Aug 2026 | Legal or regulatory | Alkem Laboratories filed the transcript of its Q1 FY2027 earnings conference call, held on 14 August 2026. Management said revenue from operations was INR3,740 crores, up close to 11% year-on-year; India sales were INR2,497 crores (up 10.3%) and international sales were INR1,222 crores (up 16%). Management said... NSE copy |
| 14 Aug 2026 | Legal or regulatory | Alkem Laboratories filed its press release and analyst presentation on Q1FY27 results (quarter ended June 30, 2026). Total revenue from operations was ₹37,402 million, up 10.9% YoY; India sales ₹24,978 million (up 10.3%) and international sales ₹12,223 million (up 16.0%). EBITDA was ₹7,661 million, a 20.5% margin,... NSE copy |
| 01 Jun 2026 | Legal or regulatory, Management change | Alkem Laboratories filed the transcript of its Q4 FY2026 earnings conference call held on 28 May 2026. Management said FY26 EBITDA crossed INR3,000 crores; Q4 total revenue from operations was INR36,033 million (up 14.6% Y-o-Y) and FY26 revenue was INR1,47,123 million (up 13.5%). Management guided that the tax rate... NSE copy |
| 28 May 2026 | Legal or regulatory | Alkem Laboratories filed its press release and analyst presentation on Q4FY26 and FY26 results, dated May 28, 2026. Q4FY26 total revenue from operations was ₹36,033 million, up 14.6% YoY; EBITDA was ₹5,174 million (14.4% margin vs 12.4% in Q4FY25); net profit after non-controlling interest was ₹2,365 million, down... NSE copy |
| 28 May 2026 | Management change | Board of Alkem Laboratories approved the audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, and the auditors gave unmodified opinions. The Board recommended a final dividend of Rs. 10 per equity share (face value Rs. 2) for FY2025-26, subject to shareholder approval... NSE copy |
| 28 May 2026 | Management change | Alkem Laboratories' board, at its meeting on 28 May 2026, approved the standalone and consolidated audited financial results for the quarter and year ended 31 March 2026, with unmodified audit opinions. The board recommended a final dividend of Rs. 10 per equity share (face value Rs. 2) for FY2026, subject to... NSE copy |
| 18 Feb 2026 | Legal or regulatory | Alkem Laboratories filed an updated investor meet presentation on Alkem MedTech's strategic way forward, for a meet held on 18 February 2026 at 4:30 p.m. The presentation cites a global MedTech market of $680 billion, projected to reach $870 billion by 2030, and an Indian MedTech market of $16 billion in 2025,... NSE copy |
| 16 Feb 2026 | Legal or regulatory | Alkem Laboratories filed an investor meet presentation on Alkem MedTech's strategic way forward, to be held on February 18, 2026 at 4:30 p.m. The presentation covers a global MedTech market of $680Bn (2025), projected to reach $870Bn by 2030, and an India market of $16Bn (2025) projected to reach $30Bn by 2030... NSE copy |
| 13 Feb 2026 | Legal or regulatory | Alkem Laboratories' board approved on 13 February 2026 the amalgamation of its wholly-owned subsidiary Adroit Biomed Limited (transferor) into the company (transferee) by a scheme under Sections 230-232 of the Companies Act, 2013. The scheme is subject to sanction by the Mumbai bench of the NCLT and to shareholder... NSE copy |
| 06 Feb 2026 | Legal or regulatory | Alkem Laboratories' board approved, on 6 February 2026, the amalgamation of Alkem Medtech Ortho Private Limited (wholly owned subsidiary of Alkem Medtech Private Limited) into Alkem Medtech Private Limited via a scheme under Sections 230-232 of the Companies Act, 2013, subject to NCLT Mumbai and Ahmedabad bench... NSE copy |
| 19 Nov 2025 | Legal or regulatory | Alkem Laboratories filed the transcript of its Q2 & H1 FY26 earnings conference call, held on 13 November 2025. Management said Q2 FY26 revenue from operations was a record INR40,010 million, up 17.2% Y-o-Y; India sales INR27,660 million (up 12.4%); U.S. sales INR7,649 million (up 28%); non-U.S. sales INR4,241... NSE copy |
| 29 May 2025 | Management change | Board of Alkem Laboratories approved the standalone and consolidated audited results for the quarter and year ended 31 March 2025. The Board recommended a final dividend of Rs. 8 per equity share of Rs. 2 each for FY 2024-25, subject to shareholder approval at the AGM. The AGM is to be held on 25 August 2025, with... NSE copy |
| 29 May 2025 | Legal or regulatory, Management change | Alkem Laboratories' board, at its meeting on 29 May 2025, approved the standalone and consolidated audited financial results for the quarter and year ended 31 March 2025, with unmodified audit opinions. The board recommended a final dividend of Rs 8 per equity share of Rs 2 each for FY2024-25, subject to... NSE copy |
| 29 May 2025 | Management change | Alkem Laboratories filed the outcome of its board meeting held on 29 May 2025, which approved audited standalone and consolidated results for the quarter and year ended 31 March 2025. The board recommended a final dividend of Rs 8 per equity share (face value Rs 2) for FY2025, subject to shareholder approval at the... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (15 in all). A list of what was filed, not a judgement of the company.